β‐Catenin splice variants and downstream targets as markers for neoplastic progression of esophageal cancer

This study characterizes the frequency of exon 3 CTNNB1 mutations and compares the expression of CTNNB1 transcript variants and downstream targets MYC and WAF1 (p21) across the neoplastic progression of esophageal squamous cell carcinomas (ESCCs). Mutational analysis was performed on 56 tumors and corresponding germline DNA, using primers to exon 3 of CTNNB1 and SSCP DNA sequencing gels. Quantitative Real Time RT‐PCR was performed on 45 foci representing the histological spectrum from normal to invasive cancer, using specific primer sets for alternative splice variants that differ by the presence (16A) or absence (16B) of a 159‐bp noncoding segment of exon 16 of CTNNB1, in conjunction with downstream targets MYC and WAF1. Two unique mutations were identified, S37F in the SxxxS repeat region, and a germline polymorphism, T59A. Thus, mutation of CTNNB1 exon 3 is a rare event in this population. RT‐PCR analysis successfully confirmed the presence of both β‐catenin splice variants in histologically normal and preneoplastic squamous epithelium, and invasive tumors of the esophagus, and identified a significant reduction in the 16A/16B ratio (P = 0.014) and an accompanying significant increase in the MYC/WAF1 expression ratio (P = 0.001) with progression from normal mucosa to dysplasia. This represents the first identification of two CTNNB1 transcripts in histologically “normal” esophageal squamous cells, squamous dysplasia, and invasive ESCC. These results show an increase in the minor mRNA (16B) isoform and changes in the expression of downstream markers consistent with increased transcription during the histological progression from normal to squamous dysplasia. Published 2005 Wiley‐Liss, Inc.

[1]  K. Silina,et al.  Alterations of pre‐mRNA splicing in cancer , 2005, Genes, chromosomes & cancer.

[2]  S. Kuersten,et al.  The power of the 3′ UTR: translational control and development , 2003, Nature Reviews Genetics.

[3]  Ming-Rong Wang,et al.  Analysis of gene expression profile induced by EMP-1 in esophageal cancer cells using cDNA Microarray. , 2003, World journal of gastroenterology.

[4]  B. Klump,et al.  C-myc gene amplification in different stages of oesophageal squamous cell carcinoma: prognostic value in relation to treatment modality. , 2003, Anticancer research.

[5]  H. Clevers,et al.  Armadillo/β-catenin signals in the nucleus – proof beyond a reasonable doubt? , 2003, Nature Cell Biology.

[6]  D. Wakelin,et al.  Upregulation of the oncogene c-myc in Barrett’s adenocarcinoma: induction of c-myc by acidified bile acid in vitro , 2003, Gut.

[7]  Hans Clevers,et al.  The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells , 2002, Cell.

[8]  Xinli Hu,et al.  Regulation of mouse kappa opioid receptor gene expression by different 3'-untranslated regions and the effect of retinoic acid. , 2002, Molecular pharmacology.

[9]  Hans Clevers,et al.  T‐cell factors: turn‐ons and turn‐offs , 2002, The EMBO journal.

[10]  F. Bosman,et al.  Beta-catenin expression and its association with prognostic factors in adenocarcinoma developed in Barrett esophagus. , 2002, American journal of clinical pathology.

[11]  R. Méndez,et al.  Translational control by CPEB: a means to the end , 2001, Nature Reviews Molecular Cell Biology.

[12]  Aubrey R. Morrison,et al.  The 3′-Untranslated Region of Murine Cyclooxygenase-2 Contains Multiple Regulatory Elements That Alter Message Stability and Translational Efficiency* , 2001, The Journal of Biological Chemistry.

[13]  N. Hu,et al.  Genetic progression and heterogeneity associated with the development of esophageal squamous cell carcinoma. , 2001, Cancer research.

[14]  N. Hu,et al.  Frequent inactivation of the TP53 gene in esophageal squamous cell carcinoma from a high-risk population in China. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  J. Feliu,et al.  β-Catenin expression pattern in primary oesophageal squamous cell carcinoma. Relationship with clinicopathologic features and clinical outcome , 2000, Virchows Archiv.

[16]  P. Polakis Wnt signaling and cancer. , 2000, Genes & development.

[17]  J. Behrens,et al.  Control of β‐Catenin Signaling in Tumor Development , 2000 .

[18]  T. Sasagawa,et al.  Alteration of β‐catenin expression in esophageal squamous‐cell carcinoma , 2000 .

[19]  M. Wolter,et al.  Expression of Bcl-2 and amplification of c-myc are frequent in basaloid squamous cell carcinomas of the esophagus. , 1999, The American journal of pathology.

[20]  I. Bièche,et al.  Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. , 1999, Cancer research.

[21]  Y. Doki,et al.  Cytoplasmic β‐catenin in esophageal cancers , 1999 .

[22]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[23]  Wan-Cai Yang,et al.  Apoptosis and its relationship with cell proliferation, p53, Waf1p21, bcl-2 and c-myc in esophageal carcinogenesis studied with a high-risk population in northern China. , 1998, World journal of gastroenterology.

[24]  V. Álvarez,et al.  Chromosome 3p loss of heterozygosity and mutation analysis of the FHIT and beta-cat genes in squamous cell carcinoma of the head and neck. , 1998, Journal of clinical pathology.

[25]  F. Molemans,et al.  Genomic organization of the human beta-catenin gene (CTNNB1). , 1996, Genomics.

[26]  S. Dawsey,et al.  Esophageal morphology from Linxian, China. Squamous histologic findings in 754 patients , 1994, Cancer.

[27]  N. Muñoz,et al.  Esophageal morphology from linxian, China: Squamous histologic findings in 754 patients , 1994, Cancer.